Quantifying the impact of the COVID-19 pandemic on gastrointestinal cancer care delivery.
colonoscopy
gastrointestinal neoplasms
hospital
oncology service
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
17
04
2021
received:
25
02
2021
accepted:
04
05
2021
pubmed:
18
6
2021
medline:
1
2
2022
entrez:
17
6
2021
Statut:
ppublish
Résumé
This study quantifies how changes in healthcare utilization and delivery during the first months of the COVID-19 pandemic have altered the presentation, treatment, and management of patients with gastrointestinal (GI) malignancies within an academic health system. Patients diagnosed with a GI malignancy (ICD10: C15-C26) who received medical care within the health system during the observation period (first 44 weeks of 2019 and 2020) were identified for a retrospective cohort study. Deidentified patient encounter parameters were collected for this observation period and separated into pre-pandemic (weeks 1-10) and early pandemic (weeks 11-20) study periods. Difference-in-difference analyses adjusted for week-specific and year-specific effects quantified the impact of the COVID-19 pandemic on care delivery between pre-pandemic and early pandemic study periods in 2020. Across all GI malignancies, the COVID-19 pandemic has been associated with a significant decline in the number of patients with new patient visits (NPVs) (p = 1.2 × 10 The COVID-19 pandemic has been associated with significant disruptions to care delivery. While these effects were appreciated broadly across GI malignancies, CRC, diagnosed and managed by periodic screening, has been affected most acutely.
Sections du résumé
BACKGROUND AND AIM
This study quantifies how changes in healthcare utilization and delivery during the first months of the COVID-19 pandemic have altered the presentation, treatment, and management of patients with gastrointestinal (GI) malignancies within an academic health system.
METHODS AND RESULTS
Patients diagnosed with a GI malignancy (ICD10: C15-C26) who received medical care within the health system during the observation period (first 44 weeks of 2019 and 2020) were identified for a retrospective cohort study. Deidentified patient encounter parameters were collected for this observation period and separated into pre-pandemic (weeks 1-10) and early pandemic (weeks 11-20) study periods. Difference-in-difference analyses adjusted for week-specific and year-specific effects quantified the impact of the COVID-19 pandemic on care delivery between pre-pandemic and early pandemic study periods in 2020. Across all GI malignancies, the COVID-19 pandemic has been associated with a significant decline in the number of patients with new patient visits (NPVs) (p = 1.2 × 10
CONCLUSIONS
The COVID-19 pandemic has been associated with significant disruptions to care delivery. While these effects were appreciated broadly across GI malignancies, CRC, diagnosed and managed by periodic screening, has been affected most acutely.
Identifiants
pubmed: 34137216
doi: 10.1002/cnr2.1427
pmc: PMC8420475
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1427Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Br J Surg. 2020 Oct;107(11):e521-e522
pubmed: 32856751
J Surg Oncol. 2021 Mar;123(4):834-841
pubmed: 33559133
JCO Clin Cancer Inform. 2020 Jul;4:657-665
pubmed: 32716647
Br J Cancer. 2017 Sep 5;117(6):888-897
pubmed: 28787432
MMWR Morb Mortal Wkly Rep. 2020 Jun 12;69(23):699-704
pubmed: 32525856
JAMA. 2020 Jul 7;324(1):96-99
pubmed: 32501493
Endoscopy. 2021 Feb;53(2):166-170
pubmed: 33080630
J Gastrointest Surg. 2020 Oct;24(10):2357-2373
pubmed: 32607860
Gastroenterology. 2020 Aug;159(2):772-774.e13
pubmed: 32376410
Nat Cancer. 2020 Jun;1(6):565-567
pubmed: 35121972
Gut. 2021 Mar;70(3):537-543
pubmed: 32690602
JAMA Netw Open. 2019 Aug 2;2(8):e199126
pubmed: 31411712
Cancer Rep (Hoboken). 2022 Jan;5(1):e1427
pubmed: 34137216
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977